A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration
Abstract
Objective This study measured the annual rate of cognitive change in patients with Alzheimer's disease and determined the effects of clinical variables on that rate. It also compared the ability of two cognitive scales to measure change over the entire range of dementia severity. Method The cognitive subscale of the Alzheimer's Disease Assessment Scale and the Blessed test for information memory and concentration were given to 111 patients with Alzheimer's disease and 72 nondemented elderly comparison subjects at 6-month intervals for up to 90 months. Longitudinal changes in scores on the cognitive subscale were measured with several different methods of data analysis. Results For the patients with Alzheimer's disease, the annual rate of change in cognitive subscale scores showed a quadratic relationship with dementia severity in which deterioration was slower for mildly and severely demented patients than for patients with moderate dementia. Gender, age at onset, and family history of dementia had no effect on the rate of cognitive deterioration. The comparison group showed a slight improvement in cognitive performance over time. All data analytic methods gave similar results. The cognitive subscale of the Alzheimer's Disease Assessment Scale was more sensitive to change in both mild and severe dementia than was the Blessed test. Conclusions These results suggest that cognitive deterioration is slow during the early and very late stages of Alzheimer's disease and more rapid…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rate of decline is known to vary by stage of dementia severity.
“Rate of decline is known to vary by stage of dementia severity,(8),(9)”
Cites
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130 · see citing works
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618 · see citing works
Self-citationA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · see citing works
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966 · see citing works
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870 · see citing works
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384 · see citing works
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · see citing works
Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K., Steinberg, M., Rabins, P. V., et al. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181faec23 · Cited by 244 · see citing works
“Rate of decline is known to vary by stage of dementia severity,(8),(9) so that survival bias may produce different estimates in prevalent vs.”
BackgroundLong-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · see citing works
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189 · see citing works
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188 · see citing works
Davis, K. L., & Powchick, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90526-x · Cited by 177 · see citing works
Self-citationRaskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167 · see citing works
Norton, M. C., Piercy, K. W., Rabins, P. V., Green, R. C., Breitner, J. C. S., Ostbye, T., Corcoran, C., Welsh-Bohmer, K. A., Lyketsos, C. G., & Tschanz, J. T. (2009) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbp052 · Cited by 139 · see citing works
Yancheva, S., Ihl, R., Nikolova, G., Panayotov, P., Schlaefke, S., Hoerr, R., & for the GINDON Study Group (2009) · Aging & Mental Health · doi:10.1080/13607860902749057 · Cited by 127 · see citing works
Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85 · see citing works
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · see citing works
Burns, A., Gauthier, S., & Perdomo, C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1746 · Cited by 71 · see citing works
Long-term progression of Alzheimer's disease in patients under antidementia drugs
Gillette‐Guyonnet, S., Andrieu, S., Nourhashemi, F., Gardette, V., Coley, N., Cantet, C., Gauthier, S., Ousset, P., Vellas, B., & REAL.FR study group (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.009 · Cited by 64 · see citing works
Perez, S. E., Sherwood, C. C., Cranfield, M. R., Erwin, J. M., Mudakikwa, A., Hof, P. R., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.12.017 · Cited by 50 · see citing works
Wallin, Å., Minthon, & Wattmo, C. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s24196 · Cited by 50 · see citing works
Wallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45 · see citing works
Wouters, H., van Gool, W. A., Schmand, B., Zwinderman, A. H., & Lindeboom, R. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2402 · Cited by 43 · see citing works
Cognitive decline in the behavioral variant of frontotemporal dementia
Diehl-Schmid, J., Bornschein, S., Pohl, C., Förstl, H., Kurz, A., & Jahn, T. (2011) · International Psychogeriatrics · doi:10.1017/s104161021000164x · Cited by 13 · see citing works
- Authors
- Stern, R. G., Mohs, R. C., Davidson, M. H., Schmeidler, J., Silverman, J. M., Kramer‐Ginsberg, E., Searcey, T., Bierer, L. M., & Davis, K. L.
- Affiliations
- Mount Sinai Hospital (US)
- Venue
- American Journal of Psychiatry
- Published
- 1994-03-01
- Volume
- 151
- Issue
- 3
- Pages
- 390-396
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1472735294
- Cited by
- 408
- References
- 2
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 7 · 2019: 5 · 2018: 10 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 11 · 2012: 17
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-02219, AG 05138, P50AG005138, P01AG002219)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, cognitive decline, dementia severity, Alzheimer's Disease Assessment Scale, longitudinal cognitive change, predictors of cognitive decline, age of onset, family history of dementia
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cognition Disorders, Humans, Longitudinal Studies, Male, Middle Aged, Probability, Psychiatric Status Rating Scales, Psychometrics, Sensitivity and Specificity, Severity of Illness Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
